^
    Back
    Association details:
    Biomarker:FLT3 mutation
    Cancer:Acute Myelogenous Leukemia
    Drug:Vanflyta (quizartinib) (FLT3 inhibitor) +
    milademetan (RAIN-32) (MDM2 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Milademetan Plus Quizartinib Combination Study in FLT3-ITD Mutant Acute Myeloid Leukemia (AML)

    Excerpt:
    ...- Part 1 (dose escalation): Has FLT3-ITD mutant (≥ 3% FLT3-ITD/total FLT3) AML (primary AML, secondary, or therapy-related AML), and has treatment failure to prior AML therapy or have relapsed after prior AML therapy...
    Trial ID:
    NCT03552029
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    ASH 2018
    Title:

    Synergistic Anti-Leukemic Activity with Combination of FLT3 Inhibitor Quizartinib and MDM2 Inhibitor Milademetan in FLT3-ITD Mutant/p53 Wild-Type Acute Myeloid Leukemia Models

    Published date:
    11/01/2018
    Excerpt:
    Combination treatment with milademetan (or DS-5272) and quizartinib demonstrated synergistic anti-leukemic activity compared to the respective single-agent treatments in FLT3 mutated and TP53 wild type cells.
    DOI:
    10.1182/blood-2018-99-115183